💊 Thuốc A-Z 🧬 Đích tác dụng 🛠 Công cụ 📚 Hướng dẫn
Tất cả thuốc Phân loại thuốc Lĩnh vực điều trị Tác dụng phụ
Hướng dẫn Từ điển thuật ngữ Dòng thời gian
So sánh Hành trình của thuốc Các họ thuốc
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Dasatinib

CHEMBL5416410 Phase 4 Đã phê duyệt Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
488.0 g/mol
LogP
3.6
Phase
4

An oral BCR-ABL and Src family kinase inhibitor used to treat chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia, including some cases resistant to imatinib. It also inhibits the Src kinase family, which may contribute to additional antitumor effects.

Khối lượng phân tử

488,0000 g/mol

LogP

3,60

TPSA

135,00 Ų

Lipinski RO5

Đạt

Lĩnh vực điều trị

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Cardiovascular Disease Respiratory Disease Non-Small Cell Lung Cancer Osteoporosis Chronic Obstructive Pulmonary Disease Alzheimer's Disease Parkinson's Disease Schizophrenia Infectious Disease Melanoma Gastroesophageal Reflux Disease Inflammatory Bowel Disease Multiple Sclerosis Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Obesity Lymphoma Breast Cancer HIV/AIDS Prostate Cancer Colorectal Cancer Leukemia

Cơ chế tác dụng

Inhibits the BCR-ABL fusion tyrosine kinase, the constitutively active oncoprotein responsible for driving chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cơ chế

Inhibits the BCR-ABL fusion tyrosine kinase, the constitutively active oncoprotein responsible for driving chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.

Cấu trúc 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1.O

                

                

                
                

                    
InChI

                    
InChI=1S/C22H26ClN7O2S.H2O/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31;/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27);1H2

                

                

                

                    
                    

                        
Molecular Formula

                        
C22H26ClN7O2S

                    

                    
                    

                        
HBD / HBA

                        
3 / 9

                    

                    
                    

                        
Liên kết có thể quay

                        
7

                    

                    
                    
                    

                        
Nguyên tử nặng

                        
33

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Câu hỏi thường gặp

                

                    
                    

                        
                        

                            
An oral BCR-ABL and Src family kinase inhibitor used to treat chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia, including some cases resistant to imatinib. It also inhibits the Src kinase family, which may contribute to additional antitumor effects.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Inhibits the BCR-ABL fusion tyrosine kinase, the constitutively active oncoprotein responsible for driving chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Dasatinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL5416410.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 3062316.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Tuyên bố miễn trách y tế

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.